BIONATURIS (BIOORGANIC R.) D2015-JUNIO
GVC GAESCO BEKA, S.V., S.A.
DCM ASESORES Dirección y Consultoría de Mercados, S.L.
PAEZ & SERRANO AUDITORIES, S.L.U.
AV DESARROLLO TECNOLOGICO 11, JEREZ DE LA FRONTERA
|2015 until 15/06|
Period Close Price
Period Last Price
Period High Price
Period Low Price
Bionaturis -established in Cadiz in 2005- is a biopharmaceutical company developing and producing biomedical products for the pharmaceutical and veterinarian sectors. Bionaturis specializes in the prevention and treatment of niche diseases, such as orphan diseases.
As value proposition Bionaturis has chosen Nature as an optimized source for the production of biopharmaceuticals, substituting the traditional industrial cumbersome steel reactors for single use, disposable and naturally occurring individual reactors: FLYLIFEÒ. FLYLIFEÒ makes use of natural resources to achieve and indeed surpass the productive capacity of traditional industry standards but utilizing up to ten-fold less space and fifteen-fold less investment. Amongst others, in niche markets where currently there is no solution, these competitive advantages provide a profitable solution and gives renewed hope to millions of worldwide patients.
Its mission is to position itself as leader within the field of new platforms for production of biopharmaceuticals for veterinary and human use, and convert itself into a worldwide reference entity for the development of orphan drugs.
To complete its mission Bionaturis has chosen a mixed business model which combines short-term income through R+D services and production for third parties (BNT-CDMO), this in combination with co-development of biopharmaceuticals, which generates incomes through licensing royalties and the completion of milestones in the medium and long term (BNT-PRODUCTS).
Year on year Bionaturis has increased the portfolio of international patents, either developed internally or acquired through license.
The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at email@example.com.
What is MaB
Financing for companies
MaB for investors
News and Publications